Navigation Links
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
Date:6/11/2009

SEATTLE, June 11 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. The SLEEP meeting attracts the largest audience of sleep specialists in world.

Circadin(R) http://www.Circadin.info) is a novel sleep medicine that has been approved by the European Commission pharmaceutical regulatory agency and the Israeli Ministry of Health for the short-term treatment of primary insomnia, characterized by poor quality of sleep in patients who are aged 55 and over. The approval is based on clinical studies showing positive effects on sleep quality, sleep induction, and most importantly next day alertness and functioning.

The new double blind placebo controlled trial with more than 790 insomnia patients aged 18-80, shows that 6 months continuous treatment with Circadin(R) is both safe and efficacious. The trial demonstrated improvements in sleep latency, quality of sleep and morning alertness particularly in elderly patients, with no withdrawal symptoms and rebound insomnia. "We are very excited about these preliminary Phase III results" said Professor Nava Zisapel, CSO of Neurim Pharmaceuticals, "because Circadin(R), previously shown to be a unique short term treatment for poor sleep quality, has now demonstrated long term efficacy and safety."

About Circadin(R)

Circadin(R) http://www.Circadin.info) is the first and only IP-protected prolonged-rele
'/>"/>

SOURCE Neurim Pharmaceuticals LTD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jubilant to Work With Endo Pharmaceuticals on Drug Development
2. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
3. ADVENTRX Pharmaceuticals Announces Financing
4. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
5. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
6. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, Chromium - Global Market Trends ,...--Global-Market-Trends.html ,, Worldwide deman...s steel, while growth in aerospace and industrial ...f chromium metal. Environmental constraints and ra...
(Date:12/1/2009)...r Richard Gephardt Brings Together A-List from New...or "Best and Brightest Forum on Medical Innovatio...SNewswire/ -- Several of New Jersey,s most promine...ne and technology gathered today at the Liberty Sc...innovation in New Jersey, and throughout the Unite...
(Date:12/1/2009)...evel storage is now available to small and medium ...ank. , (PRWEB) December 1... a medical imaging software company, announced the...ervice. The PacsDrive service enables small and me...ve medical imaging in compliance with HIPAA regula...
(Date:12/1/2009)... California and AMSTERDAM, December 1 /PRNewswire/...agnostics, announced today that,Palmetto GBA, Cali...ished,coding guidelines for the company,s MammaPri...t cancer recurrence test, which has been reimburse... the United States can now submit claims for the,M...
Breaking Biology Technology:Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2
..., Feb. 13 Advance Nanotech, Inc.,(OTC Bulletin Bo...etection,systems, announced today that at a specia...ters in New York, on February 12, 2008, a proposal... shares of Capital stock from,100,000,000 shares t...hares,present at the meeting were voted in favor o...
...s the First Latin American Country to Approve Trea...husetts, February 13, Shire plc (LSE: SHP)(NASDAQ:...ceutical company, announced that ELAPRASE(R),(idur...he treatment of,Hunter syndrome, has been approved...sion for the Protection against Sanitary Risk (COF...
...pringer journal Analytical and Bioanalytical Chemi...Lummerstorfer (31) as the recipient of its Best Pa...t solid-solid interfaces probed with infrared spec...expected to gain substantial importance in various...ceive special prominence on an ABC cover. The Awa...
Other Biology Technology:Advance Nanotech Announces Shareholder Proxy Vote Results 2Advance Nanotech Announces Shareholder Proxy Vote Results 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 4
(Date:12/2/2009)...y Mountain forest,s woodland herb population has s...derstories recover from logging, according to Purd...in portions of the forest nearly 80 years ago, the...forest floor was similar to that of undisturbed ar... of forestry and natural resources, said that cont...
(Date:12/2/2009)...tter, and other foods have done more than raise pu... also are quietly fueling a boom in the market for...ety regulations. That,s the topic of the two-part ...gineering News , (C&EN) ACS, weekly newsmagazine. ...or Correspondent Marc Reisch point out that food s...
(Date:12/2/2009)...f Georgia College of Veterinary Medicine have made...w avenues for treating Ichthyophthirius multifilii... parasite that commonly attacks freshwater fish. ,...chers found that Ich harbors two apparently symbio...e usually found free-living, and Rickettsia, which...
Breaking Biology News(10 mins):Study finds logging effects vary based on a forest's history, climate 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3Young leukemia and lymphoma patients live longer today than in years past 55090 1Young leukemia and lymphoma patients live longer today than in years past 55090 2New technique can help diagnose mesothelioma 55087 1New technique can help diagnose mesothelioma 55087 2Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 1Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 2Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 3Business Association in Denver Invites Award winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using 55085 4
...y believe that HIV vaccines are the best hope for ...dent such vaccines can be made. But while most of ...p support HIV vaccine research, a majority express...’s participation in an HIV vaccine clinical trial....telephone survey of more than 3,500 adults to asse...
...the guinea pigs for Oak Ridge National Laboratory ...tter determine whether a species has vanished. , ...2001, Fort Stewart biologists were a bit concerned... Mark Bevelhimer, an aquatic ecologist and member ...egic Environmental Research and Development Progra...
...identified for the first time a group of genes tha...m cells, a discovery that brings researchers a ste... disease treatments. , Every day, blood stem cells...y 200 billion new blood cells in the bone marrow o...od stem cells also can divide and give rise to new...
Other Biology News:Survey Uncovers Surprising Attitudes Towards HIV Vaccine Research 2Survey Uncovers Surprising Attitudes Towards HIV Vaccine Research 3Elusive salamanders have role in developing new sampling models 2Elusive salamanders have role in developing new sampling models 3Fish and chips: A fast track to understanding blood development 2
10% BSA in TBS from Upstate
Rabbit Anti-Aortic Elastin Polyclonal Antibody, Unconjugated from Abcam
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Rabbit Anti-MEF2A, phospho (Thr312) Antibody, Unconjugated from Spring Bioscience
Biology Products: